252 related articles for article (PubMed ID: 22015640)
1. The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses.
Durupt F; Koppers-Lalic D; Balme B; Budel L; Terrier O; Lina B; Thomas L; Hoeben RC; Rosa-Calatrava M
Cancer Gene Ther; 2012 Jan; 19(1):58-68. PubMed ID: 22015640
[TBL] [Abstract][Full Text] [Related]
2. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
3. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic adenoviruses for the treatment of brain tumors.
Gomez-Manzano C; Fueyo J
Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
[TBL] [Abstract][Full Text] [Related]
5. Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds.
Wold WS; Toth K
Adv Cancer Res; 2012; 115():69-92. PubMed ID: 23021242
[TBL] [Abstract][Full Text] [Related]
6. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
7. Chorioallantoic Membrane Tumor Model for Evaluating Oncolytic Viruses.
Krutzke L; Allmendinger E; Hirt K; Kochanek S
Hum Gene Ther; 2020 Oct; 31(19-20):1100-1113. PubMed ID: 32552215
[TBL] [Abstract][Full Text] [Related]
8. Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development.
Lavilla-Alonso S; Bauer MM; Abo-Ramadan U; Ristimäki A; Halavaara J; Desmond RA; Wang D; Escutenaire S; Ahtiainen L; Saksela K; Tatlisumak T; Hemminki A; Pesonen S
Cancer Gene Ther; 2012 Feb; 19(2):126-34. PubMed ID: 22095385
[TBL] [Abstract][Full Text] [Related]
9. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
10. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
11. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
[TBL] [Abstract][Full Text] [Related]
12. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.
Vähä-Koskela MJ; Kallio JP; Jansson LC; Heikkilä JE; Zakhartchenko VA; Kallajoki MA; Kähäri VM; Hinkkanen AE
Cancer Res; 2006 Jul; 66(14):7185-94. PubMed ID: 16849565
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy.
Liu Y; Deisseroth A
Cancer Gene Ther; 2006 Sep; 13(9):845-55. PubMed ID: 16710344
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic adenoviral therapy for glioblastoma multiforme.
Sonabend AM; Ulasov IV; Han Y; Lesniak MS
Neurosurg Focus; 2006 Apr; 20(4):E19. PubMed ID: 16709024
[TBL] [Abstract][Full Text] [Related]
16. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
17. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
[TBL] [Abstract][Full Text] [Related]
18. VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis.
Xiao T; Fan JK; Huang HL; Gu JF; Li LY; Liu XY
Cell Res; 2010 Mar; 20(3):367-78. PubMed ID: 19918267
[TBL] [Abstract][Full Text] [Related]
19. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
20. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
